Topiramate 200 MG Oral Tablet — RxCUI 199890
RxNorm drug concept · Semantic clinical drug
RxCUI 199890
Semantic clinical drug · SCD
● Current RxNorm concept 73 FDA products
215 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI199890
Official nameTopiramate 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped73
Package NDCs mapped215
Reported Medicaid activity (SDUD)2,644,288 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Topiramate: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
📖 Read our full Topiramate guide →
🕸️ Concept Web — How Topiramate 200 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Topiramate 200 MG Oral Tablet
RxCUI 199890 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Topiramate
38404IN
-
Topiramate
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Topamax
220343BN
-
Topamax
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Topiramate Oral Tablet
374166SCDF -
Topiramate Oral Product
1162749SCDG -
Topiramate Pill
1162750SCDG -
Topiramate Oral Tablet [Topamax]
367661SBDF -
Topamax Oral Product
1177986SBDG -
Topamax Pill
1177987SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Topiramate Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Topiramate 200 MG
316840SCDC -
Topiramate 200 MG Oral Tablet [Topamax]
151229SBD -
Topiramate 200 MG [Topamax]
564943SBDC
-
Topiramate 200 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Topiramate 200 MG
SCDC · 316840 -
Topiramate Oral Tablet
SCDF · 374166 -
Topiramate Oral Product
SCDG · 1162749 -
Topiramate Pill
SCDG · 1162750
Brand-Name Concepts
-
Topiramate 200 MG Oral Tablet [Topamax]
SBD · 151229 -
Topiramate 200 MG [Topamax]
SBDC · 564943 -
Topiramate Oral Tablet [Topamax]
SBDF · 367661 -
Topamax Oral Product
SBDG · 1177986 -
Topamax Pill
SBDG · 1177987 -
Topamax
BN · 220343
📦 FDA Products & Package NDCs
73 products · 215 package NDCs
215 package NDCs map to RxCUI 199890 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 76282-0280-60 | 60 TABLET in 1 BOTTLE (76282-280-60) | Topiramate | EXELAN PHARMACEUTICALS INC. | 2020-09-07 |
| 76282-0281-10 | 1000 TABLET in 1 BOTTLE (76282-281-10) | Topiramate | EXELAN PHARMACEUTICALS INC. | 2020-09-07 |
| 76282-0281-60 | 60 TABLET in 1 BOTTLE (76282-281-60) | Topiramate | EXELAN PHARMACEUTICALS INC. | 2020-09-07 |
| 76420-0276-30 | 30 TABLET in 1 BOTTLE (76420-276-30) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0276-60 | 60 TABLET in 1 BOTTLE (76420-276-60) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0276-90 | 90 TABLET in 1 BOTTLE (76420-276-90) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0278-30 | 30 TABLET in 1 BOTTLE (76420-278-30) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0278-60 | 60 TABLET in 1 BOTTLE (76420-278-60) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0278-90 | 90 TABLET in 1 BOTTLE (76420-278-90) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0279-30 | 30 TABLET in 1 BOTTLE (76420-279-30) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0279-60 | 60 TABLET in 1 BOTTLE (76420-279-60) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0279-90 | 90 TABLET in 1 BOTTLE (76420-279-90) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0280-30 | 30 TABLET in 1 BOTTLE (76420-280-30) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0280-60 | 60 TABLET in 1 BOTTLE (76420-280-60) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
| 76420-0280-90 | 90 TABLET in 1 BOTTLE (76420-280-90) | Topiramate | Asclemed USA, Inc. | 2022-09-09 |
Observed labelers:
Cipla USA Inc. (24) ·
Sun Pharmaceutical Industries, Inc. (22) ·
Bryant Ranch Prepack (21) ·
Unichem Pharmaceuticals (USA), Inc. (16) ·
Zydus Lifesciences Limited (16) ·
Zydus Pharmaceuticals USA Inc. (16)
· +13 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.